B Spellberg

Summary

Affiliation: Los Angeles Biomedical Research Institute
Country: USA

Publications

  1. doi request reprint Capturing the diagnosis: an internal medicine education program to improve documentation
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, Calif David Geffen School of Medicine at UCLA, Los Angeles, Calif Electronic address
    Am J Med 126:739-743.e1. 2013
  2. doi request reprint Risk factors for mortality in patients with mucormycosis
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute, Harbor University of California Los Angeles UCLA Medical Center, Los Angeles, CA, USA
    Med Mycol 50:611-8. 2012
  3. pmc A controlled investigation of optimal internal medicine ward team structure at a teaching hospital
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, California, United States of America
    PLoS ONE 7:e35576. 2012
  4. pmc The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute, Harbor University of California Los Angeles UCLA Medical Center, Torrance, CA, USA
    J Antimicrob Chemother 67:715-22. 2012
  5. doi request reprint Combination therapy for mucormycosis: why, what, and how?
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, University of California at Los Angeles, 1124 West Carson St, Torrance, CA 90502, USA
    Clin Infect Dis 54:S73-8. 2012
  6. pmc Systemic antibiotic therapy for chronic osteomyelitis in adults
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 90502, USA
    Clin Infect Dis 54:393-407. 2012
  7. doi request reprint Development of a vaccine against Staphylococcus aureus
    Brad Spellberg
    The Division of General Internal Medicine, Los Angeles Biomedical Research Institute, Harbor University of California at Los Angeles Medical Center, Los Angeles, CA, USA
    Semin Immunopathol 34:335-48. 2012
  8. ncbi request reprint Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts
    Brad J Spellberg
    Division of Infectious Diseases, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Leukoc Biol 81:632-41. 2007
  9. pmc Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge
    Brad Spellberg
    Division of Infectious Diseases, Harbor University of California Los Angeles Medical Center, Torrance, California, United States of America
    PLoS Pathog 4:e38. 2008
  10. ncbi request reprint Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development
    B Spellberg
    Division of Infectious Diseases, Harbor University of California, Los Angeles Medical Center, and the Los Angeles Biomedical Research Institute, 1124 W Carson St, Torrance, CA 90502, USA
    Infection 35:167-74. 2007

Detail Information

Publications57

  1. doi request reprint Capturing the diagnosis: an internal medicine education program to improve documentation
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, Calif David Geffen School of Medicine at UCLA, Los Angeles, Calif Electronic address
    Am J Med 126:739-743.e1. 2013
    ..At Harbor-UCLA Medical Center, a public, tertiary care, academic medical center, we implemented an educational program to enhance documentation of diagnoses and comorbidities by internal medicine resident and attending physicians...
  2. doi request reprint Risk factors for mortality in patients with mucormycosis
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute, Harbor University of California Los Angeles UCLA Medical Center, Los Angeles, CA, USA
    Med Mycol 50:611-8. 2012
    ..These factors may be useful in defining enrollment randomization stratification critieria for future clinical trials, and in supporting clinical care of patients with mucormycosis...
  3. pmc A controlled investigation of optimal internal medicine ward team structure at a teaching hospital
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, California, United States of America
    PLoS ONE 7:e35576. 2012
    ..The optimal structure of an internal medicine ward team at a teaching hospital is unknown. We hypothesized that increasing the ratio of attendings to housestaff would result in an enhanced perceived educational experience for residents...
  4. pmc The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute, Harbor University of California Los Angeles UCLA Medical Center, Torrance, CA, USA
    J Antimicrob Chemother 67:715-22. 2012
    ..To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted...
  5. doi request reprint Combination therapy for mucormycosis: why, what, and how?
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, University of California at Los Angeles, 1124 West Carson St, Torrance, CA 90502, USA
    Clin Infect Dis 54:S73-8. 2012
    ..It is critical that sponsors step forward with funding to conduct these clinical trials to determine whether outcomes from these devastating infections can be improved...
  6. pmc Systemic antibiotic therapy for chronic osteomyelitis in adults
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 90502, USA
    Clin Infect Dis 54:393-407. 2012
    ....
  7. doi request reprint Development of a vaccine against Staphylococcus aureus
    Brad Spellberg
    The Division of General Internal Medicine, Los Angeles Biomedical Research Institute, Harbor University of California at Los Angeles Medical Center, Los Angeles, CA, USA
    Semin Immunopathol 34:335-48. 2012
    ..A number of candidate vaccines are in development, raising the promise that effective vaccines against S. aureus will become available in the not-so-distant future. Possible development programs for such vaccines are discussed...
  8. ncbi request reprint Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts
    Brad J Spellberg
    Division of Infectious Diseases, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Leukoc Biol 81:632-41. 2007
    ..With continued development, this strategy to recapitulate neutrophil functions has the potential to serve as an effective alternative to granulocyte transfusions...
  9. pmc Novel insights into disseminated candidiasis: pathogenesis research and clinical experience converge
    Brad Spellberg
    Division of Infectious Diseases, Harbor University of California Los Angeles Medical Center, Torrance, California, United States of America
    PLoS Pathog 4:e38. 2008
  10. ncbi request reprint Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development
    B Spellberg
    Division of Infectious Diseases, Harbor University of California, Los Angeles Medical Center, and the Los Angeles Biomedical Research Institute, 1124 W Carson St, Torrance, CA 90502, USA
    Infection 35:167-74. 2007
    ..However, wild-card patent extension legislation is highly controversial due to concerns regarding its societal cost...
  11. ncbi request reprint Current treatment strategies for disseminated candidiasis
    Brad J Spellberg
    Division of Infectious Diseases, The Los Angeles Biomedical Institute, Harbor University of California Los Angeles Medical Center, Torrance, CA 90502, USA
    Clin Infect Dis 42:244-51. 2006
    ..glabrata or C. krusei. Central venous catheters should be removed from all patients who have disseminated candidiasis, if feasible, and antifungal therapy should be administered to all patients who have candidemia or proven candidiasis...
  12. pmc Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity
    Brad Spellberg
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California, Los Angeles, Medical Center, Torrance, CA 90502, USA
    J Infect Dis 197:967-71. 2008
    ..These data have significant implications for the development and interpretation of vaccine surrogate markers...
  13. pmc The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus
    Brad Spellberg
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, University of California at Los Angeles Medical Center, Torrance, California 90502, USA
    Infect Immun 76:4574-80. 2008
    ..These data provide the foundation for cross-kingdom vaccine development against S. aureus and Candida, which collectively cause 200,000 bloodstream infections resulting in >/=40,000 to 50,000 deaths annually in the United States alone...
  14. ncbi request reprint Carl von Clausewitz (1780-1831) and cholera: the cause of World War II?
    Brad Spellberg
    Geffen School of Medicine, University of California, Los Angeles, USA
    J Med Biogr 13:108-12. 2005
    ....
  15. pmc Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials
    Brad Spellberg
    Division of Infectious Diseases, Harbor University of California at Los Angeles Medical Center, Torrance, California 90502, USA
    Clin Infect Dis 49:383-91. 2009
    ..In the absence of placebo-controlled trials, we sought to define the magnitude of efficacy of antimicrobial agents and resulting noninferiority margins for studies of complicated skin and skin-structure infection (SSSI)...
  16. pmc Recent advances in the management of mucormycosis: from bench to bedside
    Brad Spellberg
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, 1124 West Carson St, RB2, Torrance, CA 90502, USA
    Clin Infect Dis 48:1743-51. 2009
    ..Prospective, randomized clinical trials are needed to define optimal management strategies for mucormycosis...
  17. pmc Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis
    Brad Spellberg
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson St, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 53:3122-5. 2009
    ..Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis...
  18. pmc Recent advances in the treatment of mucormycosis
    Brad Spellberg
    The Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles UCLA Medical Center, 1124 West Carson Street, Torrance, CA, 90502, USA
    Curr Infect Dis Rep 12:423-9. 2010
    ..Large-scale, prospective, randomized clinical trials are needed to define optimal management strategies for mucormycosis...
  19. ncbi request reprint Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis
    Brad J Spellberg
    Department of Medicine, Los Angeles Biomedical Research Institute at Harbor University of California, Los Angeles UCLA Medical Center, Torrance, Torrance, CA 90502, USA
    J Infect Dis 194:256-60. 2006
    ..The rAls3p-N vaccine is a promising new vaccine candidate for further exploration to prevent systemic and mucosal candidal infections...
  20. pmc The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice
    Brad J Spellberg
    Division of Infectious Diseases, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    Infect Immun 73:6191-3. 2005
    ..We now report marked efficacy with subcutaneous rAls1p-N vaccination. Efficacy is retained in neutropenic and corticosteroid-treated mice. The rAls1p-N vaccine is a promising candidate for the prevention of invasive candidiasis...
  21. pmc Novel perspectives on mucormycosis: pathophysiology, presentation, and management
    Brad Spellberg
    Department of Medicine, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, Torrance, 1124 West Carson St RB2, Torrance, CA 90502, USA
    Clin Microbiol Rev 18:556-69. 2005
    ..The underlying principles of therapy for this disease remain rapid diagnosis, reversal of underlying predisposition, and urgent surgical debridement...
  22. ncbi request reprint Mice with disseminated candidiasis die of progressive sepsis
    Brad Spellberg
    Los Angeles Biomedical Research Institute, Division of Infectious Diseases at Harbor University of California at Los Angeles Medical Center, Torrance 90502, USA
    J Infect Dis 192:336-43. 2005
    ..However, despite decades of use, little is known about the physiological characteristics of the host in this model, and the cause of death remains unclear...
  23. ncbi request reprint A phagocytic cell line markedly improves survival of infected neutropenic mice
    Brad J Spellberg
    Los Angeles Biomedical Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Leukoc Biol 78:338-44. 2005
    ..With further refinements, activated HL-60 cells have the potential to overcome the technical barriers to neutrophil transfusions...
  24. pmc Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice
    Brad Spellberg
    Division of Infectious Diseases, Harbor UCLA Research and Education Institute, St John s Cardiovascular Research Center, 1124 West Carson St, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 49:830-2. 2005
    ..05) but did not improve organ clearance. In addition, prophylactic combination therapy was not more effective than prophylactic ABLC alone...
  25. pmc Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice
    Lin Lin
    The Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, Torrance, California, USA
    PLoS Pathog 5:e1000703. 2009
    ..aureus and C. albicans from tissues. Thus, vaccine-mediated adaptive immunity can protect against both infections by targeting microbes for destruction by innate effectors...
  26. ncbi request reprint Comparison of antifungal treatments for murine fusariosis
    Brad Spellberg
    David Geffen School of Medicine at UCLA Los Angeles, CA, USA
    J Antimicrob Chemother 58:973-9. 2006
    ..Fusarium solani infections are notoriously difficult to treat. We compared the efficacy of polyenes and an echinocandin in treating murine fusariosis to identify the optimal therapeutic regimen...
  27. pmc The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice
    Mingfu Liu
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Clin Invest 120:1914-24. 2010
    ..These results suggest a unique susceptibility of patients with DKA to mucormycosis and provide a foundation for the development of new therapeutic interventions for these deadly infections...
  28. pmc Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis
    Brad Spellberg
    Department of Medicine, Research and Education Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Infect Immun 71:5756-64. 2003
    ..Furthermore, the results provide in vivo confirmation that hyphal formation by C. albicans induces type 2 or IL-10-dominant host responses in tissues...
  29. pmc Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant
    Lin Lin
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    Clin Vaccine Immunol 15:582-4. 2008
    ..Thus, protein binding, by itself, may not predict the efficacy of some vaccines with aluminum adjuvants...
  30. pmc Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae
    Ashraf S Ibrahim
    Harbor UCLA Research and Education Institute, Torrance, California 90502 UCLA School of Medicine, Los Angeles, California 90024, USA
    Antimicrob Agents Chemother 47:3343-4. 2003
    ..001) and mice treated with 0.5 mg of AmB per kg b.i.d. (P = 0.047). These data indicate that high-dose LAmB is more effective than AmB in treating murine disseminated zygomycosis...
  31. pmc The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis
    Ashraf S Ibrahim
    Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, CA 90502, USA
    J Antimicrob Chemother 65:289-92. 2010
    ..We sought to determine the potential for combination therapy with the iron chelator deferasirox + liposomal amphotericin B (LAmB) to improve the outcome of murine IPA compared with LAmB monotherapy...
  32. pmc Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein
    Beverlie Baquir
    Divisions of Infectious Diseases, Los Angeles Biomedical Research Institute, Harbor University of California at Los Angeles UCLA Medical Center, USA
    J Infect Dis 201:473-7. 2010
    ..Donors reacted to diverse immunodominant epitopes. Thus, facile humoral and cellular assays can monitor immune responses to the rAls3p-N vaccine in planned clinical trials...
  33. pmc Safety and efficacy of activated transfected killer cells for neutropenic fungal infections
    Lin Lin
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute, Harbor University of California at Los Angeles UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502, USA
    J Infect Dis 201:1708-17. 2010
    ..Invasive fungal infections cause considerable morbidity and mortality in neutropenic patients. White blood cell transfusions are a promising treatment for such infections, but technical barriers have prevented their widespread use...
  34. doi request reprint Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target
    Guanpingsheng Luo
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    J Infect Dis 201:1718-28. 2010
    ..albicans, mediating resistance to phagocyte killing. Hyr1p is a promising target for vaccine or other immunological or small molecule intervention to improve the outcomes of disseminated candidiasis...
  35. pmc The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles UCLA Medical Center, Torrance, CA, USA
    Mol Microbiol 77:587-604. 2010
    ..oryzae. Thus, FTR1 is a virulence factor for R. oryzae, and anti-Ftr1p passive immunotherapy deserves further evaluation as a strategy to improve outcomes of deadly mucormycosis...
  36. pmc Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins
    Ashraf S Ibrahim
    Los Angeles Biomedical Research Institute, Division of Infectious Diseases, Harbor UCLA Medical Center, 1124 West Carson St, St John s Cardiovascular Research Center, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 55:1768-70. 2011
    ..Continued investigation into the use of triple therapy against mucormycosis and aspergillosis is warranted...
  37. pmc Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, St John s Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor University of Californa, Los Angeles Medical Center, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 49:721-7. 2005
    ..oryzae in vivo and demonstrates an inverse dose-response effect. The potential for CAS to play a role in combination therapy against zygomycosis merits further investigation...
  38. pmc Combination echinocandin-polyene treatment of murine mucormycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 52:1556-8. 2008
    ..The efficacy of combination echinocandin-polyene therapy for mucormycosis is a class effect...
  39. pmc Posaconazole mono- or combination therapy for treatment of murine zygomycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, 90502, USA
    Antimicrob Agents Chemother 53:772-5. 2009
    ..Combination therapy was no better than LAmB alone, and posaconazole monotherapy did not improve survival or reduce fungal burden versus placebo...
  40. pmc Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?
    Ashraf S Ibrahim
    Division of Infectious Diseases, Harbor University of California at Los Angeles Medical Center, and the Los Angeles Biomedical Research Institute, Torrance, California 90502, USA
    Med Mycol 47:592-600. 2009
    ..In conclusion, mucormycosis causes considerable cost to the US health care system. Targeted deployment of a niche vaccine could decrease infection rates and mortality from mucormycosis in a cost-effective manner...
  41. pmc Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis
    Ashraf S Ibrahim
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Infect Dis 198:1083-90. 2008
    ....
  42. ncbi request reprint Deferiprone iron chelation as a novel therapy for experimental mucormycosis
    Ashraf S Ibrahim
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Antimicrob Chemother 58:1070-3. 2006
    ..Other iron chelators, including deferiprone, which do not deliver iron to R. oryzae have been described. We therefore sought to determine whether iron-chelation therapy with deferiprone would effectively treat mucormycosis...
  43. pmc Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment
    Ashraf S Ibrahim
    Division of Infectious Diseases, Harbor UCLA Medical Center, 1124 West Carson St, RB2, Torrance, CA 90502, USA
    Curr Opin Infect Dis 21:620-5. 2008
    ..Iron acquisition is a critical step in the causative organisms' pathogenetic mechanism. Therefore, abrogation of fungal iron acquisition is a promising therapeutic strategy to impact clinical outcomes for this deadly disease...
  44. pmc Comparison of lipid amphotericin B preparations in treating murine zygomycosis
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 52:1573-6. 2008
    ..ABLC was as effective as LAmB in neutropenic but not DKA mice. Low-dose ABLC was less effective than LAmB at reducing brain fungal burdens in both models...
  45. pmc Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro
    Ashraf S Ibrahim
    Division of Infectious Diseases, St John s Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Bldg RB2, 1124 West Carson Street, Torrance, CA 90502, USA
    Infect Immun 73:778-83. 2005
    ..The fact that dead R. oryzae damage human endothelial cells may, in part, explain the lack of efficacy of fungicidal agents during clinical disease...
  46. ncbi request reprint Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene
    Yue Fu
    Harbor UCLA Research and Education Institute, Torrance, CA 90502, USA
    FEMS Microbiol Lett 235:169-76. 2004
    ..These data demonstrate that we have cloned the gene encoding a R. oryzae high affinity iron permease and the putative rFtr1p is involved in assimilation of iron from iron-depleted environments...
  47. ncbi request reprint Nosocomial fungal infections: epidemiology, diagnosis, and treatment
    Joshua Perlroth
    Division of Infectious Diseases, Harbor University of California Los Angeles UCLA Medical Center, California 90502, USA
    Med Mycol 45:321-46. 2007
    ..Nevertheless, the mortality of nosocomial fungal infections remains high, and new therapeutic and preventative strategies are needed...
  48. pmc Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis
    Caitlin Reed
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, University of California at Los Angeles Medical Center, Torrance, CA, USA
    Clin Infect Dis 47:364-71. 2008
    ..g., caspofungin) are ineffective against mucormycosis. However, on the basis of preclinical data, we recently began treating rhino-orbital-cerebral mucormycosis (ROCM) with combination polyene-caspofungin therapy...
  49. pmc Mucormycosis, pseudallescheriasis, and other uncommon mold infections
    Clifford Quan
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles UCLA Medical Center, Torrance, California 90502, USA
    Proc Am Thorac Soc 7:210-5. 2010
    ..In this review, we summarize current knowledge about non-Aspergillus mold infections of the chest, with a focus on risk factors, clinical features, diagnosis, and treatment...
  50. ncbi request reprint Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles
    Loren G Miller
    Division of Infectious Diseases, Harbor UCLA Medical Center and the Los Angeles Biomedical Institute at Harbor UCLA, Torrance, California, USA
    N Engl J Med 352:1445-53. 2005
    ..Staphylococcus aureus has been a very uncommon cause of necrotizing fasciitis, but we have recently noted an alarming number of these infections caused by community-associated methicillin-resistant S. aureus (MRSA)...
  51. ncbi request reprint Type 1/Type 2 immunity in infectious diseases
    B Spellberg
    Department of Internal Medicine, Harbor University of California Los Angeles Medical Center, Torrance, CA 90509, USA
    Clin Infect Dis 32:76-102. 2001
    ..In such cases, administration of antimicrobial chemotherapy and exogenous cytokines restores systemic balance, which allows successful immune responses to clear the infection...
  52. ncbi request reprint Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation
    Loren G Miller
    Division of Infectious Diseases, Harbor University of California Los Angeles UCLA Medical Center, Torrance, CA 90509, USA
    Clin Infect Dis 44:471-82. 2007
    ..aureus infections who have risk factors for acquisition of MRSA. However, there are no prospective data examining this approach...
  53. ncbi request reprint Trends in antimicrobial drug development: implications for the future
    Brad Spellberg
    Research and Education Institute and Department of Medicine, Harbor University of California, Los Angeles Medical Center, Torrance, California 90502, USA
    Clin Infect Dis 38:1279-86. 2004
    ..Despite the critical need for new antimicrobial agents, the development of these agents is declining. Solutions encouraging and facilitating the development of new antimicrobial agents are needed...
  54. pmc The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis
    Ashraf S Ibrahim
    Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    Infect Immun 74:3039-41. 2006
    ..Immun. 73:6191-6193, 2005). Here we show that the rAls1p-N vaccine also improves survival of outbred mice from disseminated candidiasis and that it is active against multiple virulent strains of C. albicans and non-C. albicans spp...
  55. pmc Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Infect Immun 73:999-1005. 2005
    ..albicans and emphasize the potential for cell-mediated immune modulation as a prophylactic or therapeutic strategy against disseminated candidiasis...
  56. pmc Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans
    Yue Fu
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    Eukaryot Cell 7:483-92. 2008
    ..Finally, these data validate the use of a conditional overexpression/suppression genetic strategy to identify candidal virulence factors...
  57. pmc The iron chelator deferasirox protects mice from mucormycosis through iron starvation
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Clin Invest 117:2649-57. 2007
    ..As iron availability is integral to the pathogenesis of other infections (e.g., tuberculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted...

Research Grants10

  1. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad J Spellberg; Fiscal Year: 2010
    ..PNS 398/2590 (Rev. 11/07) Page - Continuation Format Page ..
  2. Adrenergic Antagonism During Murine Candidiasis
    Brad Spellberg; Fiscal Year: 2007
    ..For these reasons, the potential for adrenergic antagonism to act as an effective immunotherapy is highly meritorious of investigation in this training application. ..
  3. Activated Targeted Killer (ATAK) Cells for Invasive Fungal Infections
    Brad J Spellberg; Fiscal Year: 2010
    ..Completion of the proposed studies will enable us to create a safe and effective strategy to overcome the barriers to white blood cell transfusions, revolutionizing the treatment of infections in cancer patients. ..
  4. Mechanisms of Als vaccine protection against S. aureus
    Brad J Spellberg; Fiscal Year: 2010
    ..The insights into fundamental immunological mechanisms of protection against S. aureus will also be of extreme importance to the development of other vaccine candidates targeting S. aureus in the future. ..
  5. Activated Targeted Killer (ATAK) Cells for Invasive Fungal Infections
    Brad Spellberg; Fiscal Year: 2009
    ..Completion of the proposed studies will enable us to create a safe and effective strategy to overcome the barriers to white blood cell transfusions, revolutionizing the treatment of infections in cancer patients. ..
  6. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad Spellberg; Fiscal Year: 2009
    ..PNS 398/2590 (Rev. 11/07) Page - Continuation Format Page ..
  7. Mechanisms of Als vaccine protection against S. aureus
    Brad Spellberg; Fiscal Year: 2009
    ..The insights into fundamental immunological mechanisms of protection against S. aureus will also be of extreme importance to the development of other vaccine candidates targeting S. aureus in the future. ..
  8. Mechanisms of Als vaccine protection against S. aureus
    Brad Spellberg; Fiscal Year: 2007
    ..The insights into fundamental immunological mechanisms of protection against S. aureus will also be of extreme importance to the development of other vaccine candidates targeting S. aureus in the future. ..